Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company focused on research, development, manufacture, marketing, and out-licensing of pharmaceutical products. Its therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. Key brands include Entyvio for gastroenterology, Takhzyro for rare diseases, Gammagard Liquid for plasma therapies, Adcetris for oncology, and Vyvanse for neuroscience. The company also has a pipeline of vaccines and collaborates with numerous partners such as Arrowhead Pharmaceuticals, Denali Therapeutics, and Novavax to develop new treatments.

Takeda Pharmaceutical is listed on the New York Stock Exchange (NYSE) under the ticker symbol TAK. Its shares trade in US Dollars (USD). The company is headquartered in Japan and also has a primary listing on the Tokyo Stock Exchange, but for US investors, the NYSE listing provides access in USD.

Takeda operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company develops and produces specialty drugs, often for complex or rare conditions, as well as generic medications. Its focus on specialty areas like oncology, rare diseases, and plasma-derived therapies distinguishes it from broad-based pharmaceutical companies.

Takeda was founded in 1781 and is headquartered in Japan. It operates globally, serving markets in Japan, the United States, Europe, Canada, Latin America, China, Asia, Russia/CIS, the Middle East, Oceania, and Africa. This extensive geographic reach allows Takeda to distribute its products worldwide, leveraging its research and manufacturing capabilities across multiple regions.

Takeda generates revenue through the development, manufacture, and sale of pharmaceutical products, as well as out-licensing its technologies to other companies. Its portfolio includes blockbuster brands like Entyvio (gastroenterology), Adcetris (oncology), and Vyvanse (neuroscience). The company also earns from plasma-derived therapies such as Gammagard and Hyqvia. Additionally, Takeda has numerous licensing and collaboration agreements with partners like AbbVie, GSK, and Johnson & Johnson, which provide milestone payments and royalties. Its diversified therapeutic focus and global presence help stabilize revenue streams.